TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Completed · Phase 1/Phase 2
Conditions studied: Liver Cancer
In brief
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).
Key facts
- Study ID
- NCT00077142
- Run by
- M.D. Anderson Cancer Center
- People needed
- 37
- Starts
- 2001-04-01
- Expected to finish
- 2005-08-01
- Last updated by the study team
- 2018-10-31
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.